1. **Executive Session**  
   6:00 - 6:30  
   - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements (as provided by 33 VSA § 1998(f)(2))

2. **Introductions and Approval of DUR Board Minutes**  
   6:30 - 6:35  
   (Public Comment Prior to Board Action)

3. **DVHA Pharmacy Administration Updates**  
   6:35 - 6:45  
   - Updates  
   - Universal PA Forms

4. **Medical Director Update**  
   6:45 - 6:45  
   - Clinical Programs Update  
   - Prescriber Comments

5. **Follow-up Items from Previous Meetings**  
   6:45 - 7:00  
   - Pediatric Antipsychotic Medications  
   - Second Reconsiderations by Medical Director/Substance Abuse Unit

6. **RetroDUR/DUR**  
   7:00 – 7:15  
   - Buprenorphine with concomitant opiates, opiate combinations or tramadol

7. **Clinical Update: Drug Reviews**  
   7:15 – 8:00  
   (Public comment prior to Board action)

   **Abbreviated New Drug Reviews**
   - Giazo \(^t\) (balsalazide disodium) Oral Tablet  
   - Ilevro \(^t\) (nepafenac 0.3%) Ophthalmic Suspension  
   - Onmel \(^t\) (itraconazole) 200 mg Oral Tablet  
   - Oxtellar XR \(^t\) (oxcarbazepine) ER Oral Tablet  
   - Quillivant XR \(^t\) (methylphenidate) ER Oral Suspension  
   - TOBI Podhaler \(^t\) (tobramycin) Capsules for Inhalation  
   - Uceris \(^t\) (budesonide) ER Oral Tablets

   **Full New Drug Reviews**
   - Eliquis \(^t\) (apixaban) Oral Tablet  
   - Fulyzaq \(^t\) (crofelemer) Delayed Release Oral Tablet  
   - Nesina \(^t\), Oseni \(^t\) & Kazano \(^t\) (alogliptin, alogliptin/pioglitazone & alogliptin/metformin) Oral Tablets  
   - Tecfidera \(^t\) (dimethyl fumarate) Oral Capsule  
   - Xelanz \(^t\) (tofacitinib) Oral Tablet
8. Therapeutic Drug Classes – Periodic Review 8:00 – 8:15
   (Public comment prior to Board action)
   Class review documents available on DVHA website 07/30/2013 @ 12 Noon
   - Immunomodulators
   - Multiple Sclerosis Agents
   - Oral Anticoagulants

9. New Managed Therapeutic Drug Classes 8:15 – 8:15
   (Public comment prior to Board action)
   - None

10. Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products 8:15 – 8:25
    (Public comment prior to Board action)
    - Crinone®
    - Makenna®
    - Second Generation Cephalosporins
    - Short Acting Beta Agonist Inhalers (for January 1st 2014 implementation)

11. General Announcements 8:25 – 8:30
    Selected FDA Safety Alerts
    - Olmesartan Medoxomil: Drug Safety Communication - Label Changes To Include Intestinal Problems (Sprue-Like Enteropathy)
    - Zyprexa Relprevv (Olanzapine Pamoate): Drug Safety Communication - FDA Investigating Two Deaths Following Injection

12. Adjourn 8:30